Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Trading Down 2.4 %

Evogene stock opened at $1.65 on Friday. Evogene has a 52 week low of $1.20 and a 52 week high of $10.40. The stock has a market cap of $8.85 million, a P/E ratio of -0.37 and a beta of 1.36. The stock has a 50 day moving average of $1.78 and a 200-day moving average of $3.48.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.